Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azithromycin
Drug ID BADD_D00203
Description Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration [A174172]. It was initially approved by the FDA in 1991 [A174175]. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin [A174169]. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides [A174175]. In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine]. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.[A192546]
Indications and Usage For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, M. pneumoniae, S. pyogenes, S. aureus, S. agal
Marketing Status Prescription; Discontinued
ATC Code J01FA10; S01AA26
DrugBank ID DB00207
KEGG ID D06390
MeSH ID D017963
PubChem ID 447043
TTD Drug ID D03HJK
NDC Product Code 53002-0470; 50111-787; 68071-2672; 70710-1458; 53002-5228; 68071-4795; 0781-5789; 68788-8125; 70518-2708; 50090-4720; 71610-001; 0409-0144; 50090-2509; 62332-251; 63629-8034; 68071-1528; 63629-7784; 63629-8251; 50090-4458; 68071-4773; 59651-008; 16571-695; 42806-147; 70710-1457; 59762-3051; 55150-174; 68788-7659; 71205-196; 50090-4721; 70518-0713; 68071-4902; 55700-731; 65862-641; 24658-706; 72189-314; 70518-2562; 50090-5376; 68071-4785; 63187-189; 76420-006; 0093-2027; 0781-5793; 53002-6221; 68071-4786; 53002-2230; 70518-3217; 71205-158; 70771-1424; 68071-4711; 71205-503; 50090-5283; 42291-082; 64679-961; 71205-645; 63187-169; 63187-594; 64679-964; 68788-8124; 65862-642; 42291-084; 55695-002; 71205-253; 70518-2433; 68788-7549; 68071-2507; 76420-213; 71205-519; 53002-2228; 68788-7066; 68071-4779; 63187-093; 63629-8311; 61294-9990; 59762-3130; 69306-250; 68071-4364; 42291-083; 0781-8089; 71610-381; 61919-555; 59651-007; 68071-2543; 53002-2225; 50090-5366; 68071-5035; 42806-151; 50111-788; 62332-253; 46708-253; 69452-173; 64679-962; 59762-3140; 70518-3254; 68071-2297; 45865-536; 60760-502; 68788-7598; 50090-0984; 63187-007; 59762-3120; 68071-5058; 68071-4812; 71335-1755; 69452-172; 71205-216; 68071-1527; 68788-7307; 68071-4774; 53002-2231; 68788-7507; 63187-622; 0093-2026; 71205-021; 50090-0983; 60760-808; 68071-5238; 43386-471; 42806-149; 71335-1252; 16571-696; 70710-1460; 50111-789; 53002-2224; 71205-424; 62756-512; 24658-708; 72189-088; 38779-2246; 59762-2198; 72189-087; 68071-5082; 59762-3110; 70518-0784; 55700-784; 42806-150; 69452-171; 50090-2491; 72189-093; 55700-852; 70710-1459; 0781-8090; 0781-8091; 68071-2266; 70771-1425; 46708-058; 53002-5221; 70518-3169; 70771-1422; 70518-0599; 53002-0473; 70771-1423; 65427-310; 68071-5170; 68071-2622; 53002-0472; 68071-2529; 71335-1195; 62332-252; 72189-015; 68788-7636; 63187-604; 68071-4255; 68071-4976; 46708-057; 55695-003; 71205-566; 43386-470
Synonyms Azithromycin | Azythromycin | Sumamed | Toraseptol | Vinzam | CP-62993 | CP 62993 | CP62993 | Zithromax | Azitrocin | Azadose | Ultreon | Zitromax | Azithromycin Dihydrate | Dihydrate, Azithromycin | Azithromycin Monohydrate | Monohydrate, Azithromycin | Goxal | Zentavion
Chemical Information
Molecular Formula C38H72N2O12
CAS Registry Number 83905-01-5
SMILES CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C) C)O)(C)O)C)C)C)O)(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenia01.02.03.004--Not Available
Neutrophil count13.01.06.046--Not Available
Neutrophil count decreased13.01.06.010--
Neutrophil count increased13.01.06.011--Not Available
Ocular hyperaemia06.04.05.0040.000189%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Otitis media04.05.01.001; 11.01.05.004--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.000038%Not Available
Palpitations02.01.02.0030.000240%
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.0020.000025%Not Available
Papule23.03.03.0380.000038%Not Available
Paraesthesia17.02.06.0050.000114%
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pathogen resistance11.01.08.049--Not Available
Pertussis22.07.04.002; 11.02.23.001--Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.000025%Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Photosensitivity reaction23.03.09.003--
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.0070.000025%
Pruritus23.03.12.0010.000265%
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 12 Pages